News | February 14, 2024
Lupin launches Bromfenac Ophthalmic Solution, 0.075% in US
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
Bromfenac Ophthalmic Solution 0.075% (RLD BromSite) had estimated annual sales of USD 15 million in the U.S.
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
These re-agent and diagnostic test kits come with 99.7% accuracy
Dexamethasone is used to treat conditions such as arthritis, blood/hormone disorders, allergic reactions
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
The agreement is effective from January 1, 2024 and commercialisation commenced on February 1, 2024
Ayush is expanding beyond wellness to therapeutic wellness
_256_384.png){kind=logo}
4 FDA clearances & 61 EU MDR CE tags achieved for AI in 18 months
Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries
The initiative, “Change the Odds: Uniting to Improve Cancer Outcomes” aims to enhance awareness of and access to cancer screening, clinical trials and support
Subscribe To Our Newsletter & Stay Updated
